MktsMarkets

Supernus Pharmaceuticals, Inc.
NASDAQ: SUPNKey statistics
SUPN News
Stories mentioning SUPN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 207,705 | 211,572 | 192,103 | 165,453 | 149,824 | 174,159 | 175,689 | 168,325 |
| Cost of Goods Sold | 23,391 | 23,007 | 18,965 | 16,827 | 15,763 | 26,098 | 17,583 | 17,916 |
| Gross Profit | 184,314 | 188,565 | 173,138 | 148,626 | 134,061 | 148,061 | 158,106 | 150,409 |
| Operating Expenses | ||||||||
| Research & Development | 39,438 | 27,827 | 29,366 | 22,115 | 26,927 | 28,647 | 29,036 | 26,183 |
| Sales General & Admin | 125,173 | 122,390 | 179,678 | 93,551 | 89,944 | 79,409 | 69,753 | 85,904 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (8,332) | (3,937) | (60,231) | 12,141 | (10,256) | 21,405 | 40,845 | 22,569 |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 2,382 | 2,023 | 2,277 | 4,528 | 4,425 | 4,977 | 4,098 | 3,733 |
| Pretax Income | (5,950) | (1,914) | (57,954) | 16,669 | (5,831) | 26,382 | 44,943 | 26,302 |
| Tax Provision | (3,657) | 2,191 | (12,837) | (5,830) | 5,996 | 11,054 | 6,446 | 6,386 |
| Net Income (Loss) | (2,293) | (4,105) | (45,117) | 22,499 | (11,827) | 15,328 | 38,497 | 19,916 |
| Earnings Per Share (Basic) | (0.04) | (0.07) | (0.80) | 0.40 | (0.21) | 0.28 | 0.70 | 0.36 |
| Earnings Per Share (Diluted) | (0.04) | (0.07) | (0.80) | 0.40 | (0.21) | 0.27 | 0.69 | 0.36 |
| Weighted Average Shares Outstanding (Basic) | 57,648 | 56,451 | 56,553 | 56,025 | 55,865 | 55,100 | 55,150 | 54,979 |
| Weighted Average Shares Outstanding (Diluted) | 57,648 | 56,451 | 56,553 | 56,643 | 55,865 | 55,959 | 56,016 | 55,724 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About SUPN
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a stock listed on the Nasdaq Stock Market under the ticker symbol SUPN. It last traded at $27.62 (Nov 9, 2026, 4:00 PM ET), up 5.6% on the day. That gives Supernus Pharmaceuticals a market capitalisation of $5.4B and a price-to-earnings ratio of 15.8.
Over the past 52 weeks SUPN has traded between $25.92 and $59.68.
Revenue for the quarter ended Mar 31, 2026 was $207.7M; a net loss of $2.3M. Revenue was up 38.6% from $149.8M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $207.7M | -$2.3M | -1.1% |
| Dec 31, 2025 | $211.6M | -$4.1M | -1.9% |
| Sep 30, 2025 | $192.1M | -$45.1M | -23.5% |
| Jun 30, 2025 | $165.5M | $22.5M | 13.6% |
From Supernus Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…